Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ekaterina S. Kropacheva"'
Autor:
Elena N. Krivosheeva, Andrey L. Komarov, Elizaveta P. Panchenko, Maria B. Khakimova, Ekaterina S. Kropacheva, Olga A. Pogorelova, Tatyana V. Balakhonova, Elena V. Titaeva, Anatoly B. Dobrovolsky, Damir M. Galyautdinov, Elina E. Vlasova
Publikováno v:
Терапевтический архив, Vol 96, Iss 7, Pp 683-689 (2024)
Aim. To evaluate the prognostic value of GDF-15 in relation the development of bleeding and events in stable CAD patients, receiving combined antithrombotic therapy. Materials and methods. The data was obtained from the prospective registry REGATA
Externí odkaz:
https://doaj.org/article/ab1fc0ec63a84d55b606aeefc59edcd2
Publikováno v:
Терапевтический архив, Vol 94, Iss 12, Pp 1374-1380 (2023)
Background. It is necessary to strive to resume anticoagulants for patients with atrial fibrillation who have a high risk of thrombosis after the development of large bleeding. Due to the fact that death in these patients is caused not by a recurrenc
Externí odkaz:
https://doaj.org/article/2164a8e952ac4954a2f57cc20550156b
Autor:
Irina E. Chazova, Sergei P. Golitsyn, Juliya V. Zhernakova, Ekaterina A. Zheleznova, Ekaterina S. Kropacheva, Nikolai Iu. Mironov, Marina V. Kostiukevich, Lada Iu. Laiovich, Madina D. Utsumueva, Iuliia A. Iuricheva, Alexander Yu. Litvin, Evgeniia M. Elfimova, Anatolii N. Rogoza, Elizaveta P. Panchenko
Publikováno v:
Системные гипертензии, Vol 18, Iss 3, Pp 105-128 (2021)
Arterial hypertension (AH) is a leading risk factor for cardiovascular disease as well as it is the most common, independent and potentially reversible risk factor for atrial fibrillation (AF). AH contributes to the occurrence and maintenance of AF d
Externí odkaz:
https://doaj.org/article/a62932e2890b4be5b090cec8bd168e61
Autor:
Ekaterina S. Kropacheva, Mariia B. Khakimova, Elena N. Krivosheeva, Oksana A. Zemlyanskaya, Elizaveta P. Panchenko
Publikováno v:
Терапевтический архив, Vol 93, Iss 9, Pp 1037-1043 (2021)
Background. The rate of major bleeding in patients with atrial fibrillation receiving oral anticoagulants is 25% per year. Gastrointestinal bleedings are at least a half of major hemorrhagic complications. Currently, there is no optimal scale to calc
Externí odkaz:
https://doaj.org/article/95de1ac080cc44c688844fc284f355f6
Autor:
Ekaterina S. Kropacheva
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 115-129 (2018)
The review deals with the main trials devoted to the study of genetic markers of individual variability in drug response to antithrombotic agents. The first part describes the studies of the genes encoding the platelet receptor subunits studied in th
Externí odkaz:
https://doaj.org/article/777408c441404f12830d9313e229075a